{Reference Type}: Journal Article
{Title}: Arrhythmia-Induced Cardiomyopathy: JACC State-of-the-Art Review.
{Author}: Shoureshi P;Tan AY;Koneru J;Ellenbogen KA;Kaszala K;Huizar JF;
{Journal}: J Am Coll Cardiol
{Volume}: 83
{Issue}: 22
{Year}: 2024 Jun 4
{Factor}: 27.203
{DOI}: 10.1016/j.jacc.2024.03.416
{Abstract}: Arrhythmias frequently accompany heart failure and left ventricular dysfunction. Tachycardias, atrial fibrillation, and premature ventricular contractions can induce a reversible form of dilated cardiomyopathy (CM) known as arrhythmia-induced CM (AiCM). The intriguing question is why certain individuals are more susceptible to AiCM, despite similar arrhythmia burdens. The primary challenge is determining the extent of arrhythmias' contribution to left ventricular systolic dysfunction. AiCM should be considered in patients with a mean heart rate of >100 beats/min, atrial fibrillation, or a PVC burden of >10%. Confirmation of AiCM occurs when CM reverses upon eliminating the responsible arrhythmia. Therapy choice depends on the specific arrhythmia, patient comorbidities, and preferences. After left ventricular function is restored, ongoing follow-up is essential if an abnormal myocardial substrate persists. Accurate diagnosis and treatment of AiCM have the potential to enhance patients' quality of life, improve clinical outcomes, and reduce hospital admissions and overall health care costs.